Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia (Phase II Feasibility)
2010-022897-14Phase 2Completed
- Sponsor
- NTNU
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of celecoxib in cachexia, non-small cell lung cancer (NSCLC) and pancreatic cancer (PC) (2 arms), sponsored by NTNU. Primary endpoint: Feasibility of recruitment. Started May 2011; status: completed.
02
Drugs
celecoxib
03
Conditions
cachexianon-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2010-022897-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022897-14.